Breaks Categories: News

WednesdayMay 13, 2026 9:20 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Next-Generation CNS Drug Delivery

Oncotelic Therapeutics (OTCQB: OTLC) was featured in BioMedWire editorial coverage examining the growing urgency around effective central nervous system drug delivery, with the company highlighted for its proprietary intranasal nose-to-brain delivery platform designed to bypass the blood-brain barrier and deliver therapeutics directly to the brain. The editorial points to rising global Alzheimer’s cases and increased biodefense focus as major catalysts driving demand for faster, more targeted CNS delivery technologies, positioning Oncotelic’s platform-based approach as part of a broader shift toward delivery innovation as a critical determinant of therapeutic success. The coverage also places Oncotelic alongside major biopharma and advanced therapeutics…

Continue Reading

WednesdayMay 13, 2026 9:10 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Spotlighted in BioMedWire Editorial on AI-Driven Impairment Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) was featured in BioMedWire editorial coverage highlighting the growing demand for real-time, noninvasive impairment detection technologies, with the company positioned as a differentiated player leveraging artificial intelligence and voice analysis to identify intoxication from brief speech recordings. The editorial underscores the limitations of conventional detection tools such as breathalyzers, blood draws and urine testing, noting MindBio’s focus on scalable, real-time assessment across multiple substances for potential applications in workplace safety, law enforcement, healthcare and public health. The coverage also…

Continue Reading

WednesdayMay 13, 2026 9:00 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Enters $4.4 Million Registered Direct Offering

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced a definitive agreement for the purchase and sale of 2,135,923 shares of common stock, or pre-funded warrants in lieu thereof, at $2.06 per share in a registered direct offering expected to generate approximately $4.4 million in gross proceeds. The company also announced a concurrent private placement of unregistered warrants and said it plans to create an independent business entity composed of its AI platform, withZeta.ai, and related technologies and personnel. To view the full press release, visit https://ibn.fm/6Dy4I ABOUT LANTERN PHARMA INC. Lantern Pharma Inc. (Nasdaq: LTRN) is a…

Continue Reading

TuesdayMay 12, 2026 11:52 am

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation 

This article has been disseminated on behalf of SureNano Science Ltd.  and may include paid advertising.  SureNano Science (CSE: SURE) (OTCQB: SURNF) announced its placement in a BioMedWire editorial examining the evolution of GLP-1 therapies and emerging innovation in obesity and metabolic disease treatment. The editorial highlights SureNano’s subsidiary GlucaPharm Inc. and its GEP-44 program, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in the rapidly expanding GLP-1 market, as demand continues to grow for next-generation therapies targeting obesity, type 2 diabetes and related chronic conditions. To view the full press release, visit https://ibn.fm/sv4Fw About SureNano Science Ltd. SureNano Science Ltd. (CSE: SURE) is a Canadian life sciences company focused on acquiring, developing, and advancing innovative pharmaceutical…

Continue Reading

TuesdayMay 12, 2026 11:08 am

BioMedNewsBreaks — Qdrant Powers Sapu AI Platform Indexing 28 Million PubMed Abstracts to Accelerate Cancer Research 

Qdrant’s vector database infrastructure supports the AI-powered research platform used by SAPU Bioscience, a subsidiary of Oncotelic Therapeutics Inc. (OTCQB: OTLC), enabling large-scale biomedical literature analysis SAPU’s platform has indexed 28 million PubMed abstracts into a single searchable collection, supporting AI-assisted research workflows and peer-reviewed scientific output The AI ecosystem aligns with Oncotelic’s broader strategy of integrating artificial intelligence, nanoparticle development and accelerated drug discovery platforms In a blog post by Daniel Azoulai, Qdrant highlighted how Sapu, an early-stage biopharmaceutical company developing treatments for hard-to-treat cancers, uses Qdrant Cloud infrastructure to power an AI research platform capable of indexing and querying all 28 million PubMed abstracts in a single searchable collection, helping accelerate biomedical…

Continue Reading

TuesdayMay 12, 2026 10:00 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) CEO Featured on TechMediaWire Podcast Discussing AI Voice Detection Platform

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Founder and CEO Justin Hanka joined the latest episode of the TechMediaWire Podcast to discuss the company’s artificial intelligence-driven voice analysis technology designed to detect drug and alcohol intoxication through noninvasive speech analysis. During the interview, Hanka outlined the limitations of traditional testing methods and described MindBio’s commercial focus on regulated workplace environments such as mining, where the company believes its scalable detection platform could improve safety by expanding real-time intoxication screening capabilities. To view the full press release,…

Continue Reading

TuesdayMay 12, 2026 9:20 am

BioMedNewsBreaks – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) Featured in BioMedWire Editorial on AI-Powered Intoxication Detection

This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) announced its placement in a BioMedWire editorial exploring emerging technologies aimed at improving intoxication detection across law enforcement, workplace safety and healthcare settings. The editorial highlights MindBio’s development of an artificial intelligence-driven voice analysis platform designed to detect real-time impairment from short speech samples, positioning the company within a growing movement toward noninvasive diagnostic technologies with potential applications across public safety, regulatory enforcement and health monitoring. To view the full press release, visit https://ibn.fm/Ib2KB About MindBio Therapeutics Corp. MindBio is…

Continue Reading

TuesdayMay 12, 2026 9:10 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on CNS Drug Delivery Innovation

Oncotelic Therapeutics (OTCQB: OTLC) announced its placement in a BioMedWire editorial examining emerging breakthroughs in central nervous system drug delivery and the growing market opportunities tied to overcoming the blood-brain barrier. The editorial highlights Oncotelic’s proprietary intranasal nose-to-brain delivery platform, which is designed to enable rapid, targeted therapeutic access to the brain, positioning the company within a broader industry effort to advance next-generation treatments for neurological disease, biodefense applications and other CNS-related conditions. To view the full press release, visit https://ibn.fm/Y8E3U About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy…

Continue Reading

MondayMay 11, 2026 1:40 pm

BioMedNewsBreaks — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly 

This article has been disseminated on behalf of SureNano Science Ltd.  and may include paid advertising.  SureNano Science (CSE: SURE) (OTCQB: SURNF), through subsidiary GlucaPharm Inc., is advancing GEP-44, a patented triple agonist peptide targeting GLP-1 and peptide YY receptors as the global obesity and metabolic disease market continues to expand. The company is pursuing a differentiated approach focused on improved efficacy, tolerability and delivery flexibility in a therapeutic category that has become one of the most commercially significant in modern healthcare, with long-term market projections exceeding $200 billion. SureNano is part of an increasingly competitive GLP-1 landscape led by Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen…

Continue Reading

MondayMay 11, 2026 1:18 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Launches Pilot Study for On-Demand 12-Lead ECG Patch in Coronary Artery Disease Patients 

HeartBeam (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG patch in approximately 50 patients with suspected coronary artery disease at two hospitals in Belgrade, Serbia. The study will compare synthesized 12-lead ECG readings generated by the company’s patch immediately following exercise stress testing against standard 12-lead ECGs, supporting HeartBeam’s regulatory strategy for a device designed to expand ambulatory cardiac monitoring beyond rhythm assessment into ischemia detection within an established approximately $2 billion patch-based monitoring market.  To view the full press release, visit https://ibn.fm/x7016 About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring…

Continue Reading